<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clinical, hematologic, and cytogenetic data of nine patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t), classified according to the French-American-British Cooperative Group for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), are reported </plain></SENT>
<SENT sid="1" pm="."><plain>At diagnosis, eight out of nine cases, had chromosomal abnormalities and three out of nine developed <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Karyotype studies allowed individualization of two groups of patients: five with nonrandom major karyotype abnormalities (MAKA) including hypodiploidy, chromosomes 5 and 7 involvement, at least four other abnormalities, and a poor prognosis (survival always under 3.5 months); and four patients with either <z:mpath ids='MPATH_458'>normal</z:mpath> karyotypes or minor karyotype abnormalities (MIKA) (no more than three abnormalities) and a better prognosis (survival from 14 to 38 months) </plain></SENT>
<SENT sid="3" pm="."><plain>Karyotype appears to be a major prognostic factor among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t </plain></SENT>
</text></document>